Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Belinda Welsh

Dr Belinda Welsh

Rosacea – Smarter Diagnosis and State of the Art Care

A/Prof Ralph Audehm & Prof Genie Pedagogos

A/Prof Ralph Audehm & Prof Genie Pedagogos

The Role of SGLT2 Inhibitors in Preventing Dialysis

Prof Jason Ong

Prof Jason Ong

Syphilis is on the Rise – What GPs Can do to Turn it Around

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

COPD Cases

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022